Literature DB >> 22791417

The clinical spectrum of Castleman's disease.

Angela Dispenzieri1, James O Armitage, Matt J Loe, Susan M Geyer, Jake Allred, John K Camoriano, David M Menke, Dennis D Weisenburger, Kay Ristow, Ahmet Dogan, Thomas M Habermann.   

Abstract

Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10-year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5-year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22791417      PMCID: PMC3900496          DOI: 10.1002/ajh.23291

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  51 in total

1.  Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases.

Authors:  D D Weisenburger; B N Nathwani; C D Winberg; H Rappaport
Journal:  Hum Pathol       Date:  1985-02       Impact factor: 3.466

2.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1987. A 59-year-old woman with progressive polyneuropathy and monoclonal gammopathy.

Authors: 
Journal:  N Engl J Med       Date:  1987-03-05       Impact factor: 91.245

3.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 4.  Castleman's disease and related disorders.

Authors:  G Frizzera
Journal:  Semin Diagn Pathol       Date:  1988-11       Impact factor: 3.464

5.  Multicentric angiofollicular lymph node hyperplasia. Pathology of the spleen.

Authors:  D D Weisenburger
Journal:  Am J Surg Pathol       Date:  1988-03       Impact factor: 6.394

6.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients.

Authors:  G Frizzera; P M Banks; G Massarelli; J Rosai
Journal:  Am J Surg Pathol       Date:  1983-04       Impact factor: 6.394

7.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Authors:  G Frizzera; B A Peterson; E D Bayrd; A Goldman
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

8.  Peripheral neuropathy associated with Castleman's disease.

Authors:  M Donaghy; P Hall; J Gawler; N A Gregson; S Leibowitz; S Jitpimolmard; R H King; P K Thomas
Journal:  J Neurol Sci       Date:  1989-02       Impact factor: 3.181

9.  The Crow-Fukase syndrome: a study of 102 cases in Japan.

Authors:  T Nakanishi; I Sobue; Y Toyokura; H Nishitani; Y Kuroiwa; E Satoyoshi; T Tsubaki; A Igata; Y Ozaki
Journal:  Neurology       Date:  1984-06       Impact factor: 9.910

10.  Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS).

Authors:  N A Lachant; N C Sun; L A Leong; R S Oseas; H E Prince
Journal:  Am J Clin Pathol       Date:  1985-01       Impact factor: 2.493

View more
  69 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

Review 2.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

4.  Castleman's disease of the spleen.

Authors:  Hee-Jeong Lee; Ho-Jong Jeon; Sang-Gon Park; Chi-Young Park
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

5.  Calcifying fibrous tumor of the small intestine associated with Castleman-like lymphadenopathy.

Authors:  Genaro Valladolid; Elliot Weisenberg; Ramamoorthy Sundaresan; Ajay V Maker
Journal:  J Gastrointest Surg       Date:  2014-01-23       Impact factor: 3.452

Review 6.  Transplantation in rare lymphoproliferative and histiocytic disorders.

Authors:  Alexis Cruz-Chacon; John Mathews; Ernesto Ayala
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

7.  Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions.

Authors:  Xiaosheng Fang; Zhongling Sun; Zijun Y Xu-Monette; Ken H Young
Journal:  Oncologist       Date:  2020-11-30

Review 8.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

Review 9.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01

10.  Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion.

Authors:  Alkim Oden Akman; Ozge Basaran; Derya Ozyoruk; Unsal Han; Tulin Sayli; Nilgun Cakar
Journal:  Eur J Pediatr       Date:  2015-11-27       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.